Loxo Oncology, Inc.
http://www.loxooncology.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Loxo Oncology, Inc.
Scorpion Nabs $108m, Biopharma Veterans For Precision Oncology 2.0
The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.
FDA OKs Blueprint/Roche's Gavreto As Rival To Lilly's Retevmo
Regulators in the US have approved Gavreto for metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, setting the stage for a head-to-head battle for market share with Eli Lilly's Retevmo.
Roche Backs Blueprint's Precision Therapy Pralsetinib To Challenge Lilly
The collaboration between the Swiss major and Blueprint Medicines, which could be worth up to $1.7bn, should help pralsetinib provide stiff competition to Eli Lilly's RET mutation drug Retevmo.
New Drug Launches Worldwide Dipped In 2019
The number of new active substances launched in their first market in 2019 dropped as 2018’s superlative performance gave way to something more usual.